Trending...
- Customized Stations Available for Jeron Pro-Alert™ Area of Rescue System
- 99% of lab professionals impacted by medical couriers, survey finds
- Mayor Brandon Johnson Launches Public Application To Join Chicago's Reparations Task Force
~ Chicago, IL - Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will be presenting new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in Chicago from May 30th to June 3rd, 2025.
The data presented will demonstrate the anti-tumor activity of pelareorep in pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer known for its poor prognosis and limited treatment options. This is an important development as there are currently few effective treatments available for this type of cancer.
According to Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech, "Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist." He further explains that in multiple studies, pelareorep has shown its ability to engage the immune system and attack pancreatic cancer tumors. This has the potential to improve outcomes for patients battling this difficult-to-treat cancer.
The presentation at ASCO will include abstract number 2562 titled "Role of pelareorep in activating anti-tumor immunity in PDAC." It will be presented as a poster during the Developmental Therapeutics – Immunotherapy session on June 2nd from 1:30 - 4:30 p.m. CT.
More on illi News
The abstracts for the conference will be published on the ASCO website on May 22nd at 5:00 p.m. ET.
The GOBLET study is a phase 1/2 multiple indication study being conducted at 17 centers in Germany and managed by AIO-Studien-gGmbH. The primary endpoints of the study are objective response rate (ORR) and/or disease control rate assessed at week 16, as well as safety. The study also includes key secondary and exploratory endpoints such as additional efficacy assessments and evaluation of potential biomarkers.
The study comprises five treatment groups, including pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line advanced/metastatic pancreatic cancer patients; pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients; pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients; pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients; and pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in newly diagnosed metastatic PDAC patients.
If any cohort meets pre-specified efficacy criteria during Stage 1 of the study, it may be advanced to Stage 2 and enroll additional patients.
More on illi News
AIO-Studien-gGmbH (AIO) is a non-profit organization focused on promoting science and research in medical oncology. It has become a successful sponsor and study management company both nationally and internationally.
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has shown promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It works by inducing anti-cancer immune responses and promoting an inflamed tumor phenotype, turning "cold" tumors "hot," through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has also shown synergies with multiple approved oncology treatments. The company is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it moves towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA.
For more information, please visit www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and Twitter @oncolytics.
Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
This press release contains forward-looking statements about the potential benefits and advancements of pelareorep in treating various types of cancer. These
The data presented will demonstrate the anti-tumor activity of pelareorep in pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer known for its poor prognosis and limited treatment options. This is an important development as there are currently few effective treatments available for this type of cancer.
According to Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech, "Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist." He further explains that in multiple studies, pelareorep has shown its ability to engage the immune system and attack pancreatic cancer tumors. This has the potential to improve outcomes for patients battling this difficult-to-treat cancer.
The presentation at ASCO will include abstract number 2562 titled "Role of pelareorep in activating anti-tumor immunity in PDAC." It will be presented as a poster during the Developmental Therapeutics – Immunotherapy session on June 2nd from 1:30 - 4:30 p.m. CT.
More on illi News
- InventHelp Inventor Develops New Makeup Application Machine (CHK-1097)
- New Professional Association to Study Principles of Hospitality Applied to the Delivery of Healthcare
- Clinical Endpoints Successfully Met in Study for Groundbreaking 12-Lead ECG Synthesis Technology Allowing Software Application to FDA: HeartBeam, Inc
- DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Medical Express Ambulance, Inc. Customers Whose Data May Have Been Compromised
- Boston Industrial Solutions, Inc. Unveils Natron® 504N UV LED Inks Designed for EPSON Printheads
The abstracts for the conference will be published on the ASCO website on May 22nd at 5:00 p.m. ET.
The GOBLET study is a phase 1/2 multiple indication study being conducted at 17 centers in Germany and managed by AIO-Studien-gGmbH. The primary endpoints of the study are objective response rate (ORR) and/or disease control rate assessed at week 16, as well as safety. The study also includes key secondary and exploratory endpoints such as additional efficacy assessments and evaluation of potential biomarkers.
The study comprises five treatment groups, including pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line advanced/metastatic pancreatic cancer patients; pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients; pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients; pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients; and pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in newly diagnosed metastatic PDAC patients.
If any cohort meets pre-specified efficacy criteria during Stage 1 of the study, it may be advanced to Stage 2 and enroll additional patients.
More on illi News
- Kavelle Christie: Trump's First 100 Days Mark Alarming Breakdown in Healthcare, Public Health, and Freedoms
- Naperville: 100 Block Locust Court Structure Fire
- Naperville: Bulk Brush Collection to Help Residents With Spring Yard Clean-Ups
- Late-Breaking Research from SK Life Science Labs at AACR Annual Meeting Shows p300-Selective Degraders are Potent Growth Inhibitors in Models of Aggressive Prostate Cancers and Solid Tumors
- OpenSSL Technical Advisory Committee Elections Now Open – Cast Your Vote
AIO-Studien-gGmbH (AIO) is a non-profit organization focused on promoting science and research in medical oncology. It has become a successful sponsor and study management company both nationally and internationally.
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has shown promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It works by inducing anti-cancer immune responses and promoting an inflamed tumor phenotype, turning "cold" tumors "hot," through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has also shown synergies with multiple approved oncology treatments. The company is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it moves towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA.
For more information, please visit www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and Twitter @oncolytics.
Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
This press release contains forward-looking statements about the potential benefits and advancements of pelareorep in treating various types of cancer. These
Filed Under: Business
0 Comments
Latest on illi News
- Chicago: Mayor Johnson Announces $2 Million In New Round of Community Grant Recipients
- People & Stories/Gente y Cuentos Announces New Board Leadership & Corporate Partnership Initiative
- Concert Violinist Addison Teng Redefines Music Education for a New Generation
- How to Fast-Track Your Way to the Top with The Code
- Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
- Naperville Residents Invited to 'Chat with the Chief' on May 1
- Ultra High Net Worth Team Partners with Arkadios Capital, Establishing Boutique Firm KRM Investment Counsel
- Lyricalmar Set To Release Powerful New Ep "MARCHIVES" May 16
- Water Quality Association's 50th Anniversary Makes a Splash with Interactive Digital Artwork
- Charleston, SC - ACSEC offers Rain Barrels Through Annual Program
- Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
- Baltimore Author Crafts Space Opera Where Human Questions Outshine Galactic Scale
- Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
- OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges
- Crescent Grove Advisors Marks a Decade of Independence
- MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
- "The Eyes Have It" a Short Story by Philip K. Dick Now Available on Audiobook
- New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY
- Locus Robotics Surpasses 5 Billion Pick Milestone, Accelerating Global Adoption of Mobile Warehouse Automation USA - English USA - English